Korsana Biosciences KRSA
$37.56 +$2.11 (+5.95%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $37.56 0.00%
Open$35.63
Prev close$35.45
Day range$34.08 – $39.41
Volume265.2K
Market cap$1.71B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$48.27M-119.9% YoY
Net profit-$46.43M-113.7% YoY
Diluted EPS-$3.19+25.4% YoY
Free cash flow-$10.61M
Operating cash flow-$10.61M
Revenue, last 4 quarters
Net profit, last 4 quarters
Diluted EPS by quarter
Profitability & balance sheet
Return on equity-23.2%
Return on assets-19.7%
Return on invested capital-24.6%
Current ratio10.42
Liabilities / assets15.3%
Cash & investments$456.22M
Total debt$984,000.00
Net cash (debt)$455.24M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Research & Development | $42.14M | $15.51M | $32.79M | $12.05M | $20.48M |
| -General & Admin Expense | $6.14M | $2.94M | $4.51M | $2.92M | $1.48M |
| Selling and Admin Expenses | $6.14M | $2.94M | $4.51M | $2.92M | $1.48M |
| Operating Expense | $48.27M | $18.45M | $37.29M | $14.97M | $21.96M |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Profit | -$48.27M | -$18.45M | -$37.29M | -$14.97M | -$21.96M |
| Net Non-Operating Interest Income (Expense) | $1.85M | $1.09M | $1.65M | $1.28M | $234,000.00 |
| Non-Operating Interest Income | $1.85M | $1.09M | $1.65M | $1.28M | $234,000.00 |
| Pretax Profit | -$46.43M | -$17.36M | -$35.64M | -$13.69M | -$21.72M |
| Net Profit | -$46.43M | -$17.36M | -$35.64M | -$13.69M | -$21.72M |
| Net Income to Parent Company | -$46.43M | -$17.36M | -$35.64M | -$13.69M | -$21.72M |
| Basic EPS | -$3.19 | -$3.42 | -$7.07 | -$2.69 | -$4.27 |
| Diluted EPS | -$3.19 | -$3.42 | -$7.07 | -$2.69 | -$4.27 |
| Net Income to Common Stockholders | -$46.43M | -$17.36M | -$35.64M | -$13.69M | -$21.72M |
| Profit from Continuing Operations | -$46.43M | -$17.36M | -$35.64M | -$13.69M | -$21.72M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2025 Q4 | 2025 ANNUAL | 2024 ANNUAL |
|---|---|---|---|---|---|
| Long Term Debt and Capital Lease Obligation | $984,000.00 | $917,000.00 | – | – | – |
| -Long Term Capital Lease Obligation | $984,000.00 | $917,000.00 | – | – | – |
| Convertible preferred securities | $24.96M | $175.54M | $175.54M | $175.54M | $9.96M |
| Total Equity | $391.56M | -$63.28M | -$33.97M | -$33.97M | $66,000.00 |
| Stockholders' Equity | $391.56M | -$63.28M | -$33.97M | -$33.97M | $66,000.00 |
| Capital Stock | $0.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $0.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Retained Earnings | -$113.03M | -$66.60M | -$35.73M | -$35.73M | -$88,000.00 |
| Payables | $1.61M | $462,000.00 | $176,000.00 | $176,000.00 | $68,000.00 |
| Total Current Liabilities | $44.20M | $12.55M | $12.49M | $12.49M | $78,000.00 |
| Total Liabilities | $70.52M | $189.43M | $188.56M | $188.56M | $10.04M |
| Other Non-Current Assets | $101,000.00 | $3.12M | – | – | – |
| -Gross PPE | $1.33M | $1.23M | – | – | – |
| Net PPE | $1.33M | $1.23M | – | – | – |
| Total Non-Current Assets | $1.44M | $4.35M | $0.00 | $0.00 | $0.00 |
| Other Current Assets | $4.43M | $639,000.00 | $461,000.00 | $461,000.00 | – |
| Non-Current Accrued Expenses | $376,000.00 | $430,000.00 | $538,000.00 | $538,000.00 | $0.00 |
| Total Non-Current Liabilities | $26.32M | $176.88M | $176.08M | $176.08M | $9.96M |
| Other Current Liabilities | $13.51M | $844,000.00 | – | – | – |
| -Current Capital Lease Obligation | $287,000.00 | $191,000.00 | – | – | – |
| Short-Term Debt and Capital Lease Obligation | $287,000.00 | $191,000.00 | – | – | – |
| Current Accrued Expenses | $28.79M | $11.05M | $11.94M | $11.94M | $10,000.00 |
| -Accounts Payable | $1.61M | $462,000.00 | $176,000.00 | $176,000.00 | $68,000.00 |
| -Cash and Cash Equivalents | $456.22M | $121.17M | $154.14M | $154.14M | $10.11M |
| Additional Paid-In Capital | $504.59M | $3.32M | $1.76M | $1.76M | $153,000.00 |
| Cash and Cash Equivalents & Short-Term Investments | $456.22M | $121.17M | $154.14M | $154.14M | $10.11M |
| Total Current Assets | $460.65M | $121.81M | $154.60M | $154.60M | $10.11M |
| Total Assets | $462.08M | $126.16M | $154.60M | $154.60M | $10.11M |
Cash flow
| Line item | 2025 Q4 | 2025 ANNUAL | 2024 ANNUAL |
|---|---|---|---|
| Free Cash Flow | -$10.61M | -$22.41M | $44,000.00 |
| Beginning Cash Balance | $163.88M | $10.11M | $0.00 |
| Net Change in Cash | -$9.75M | $144.03M | $10.11M |
| Ending Cash Balance | $154.14M | $154.14M | $10.11M |
| Proceeds from Stock Option Exercised | $860,000.00 | $860,000.00 | $100,000.00 |
| Net Preferred Stock Issuance | $0.00 | $165.57M | $9.96M |
| Financing Cash Flow | $860,000.00 | $166.43M | $10.06M |
| -Change in Payables and Accrued Expense | $1.95M | $12.09M | $78,000.00 |
| -Change in Prepaid Assets | -$221,000.00 | -$461,000.00 | $0.00 |
| Change in Working Capital | $1.72M | $11.63M | $78,000.00 |
| Net Income from Continuing Operations | -$13.69M | -$35.64M | -$88,000.00 |
| Net cash flow from continuing operations | -$10.61M | -$22.41M | $44,000.00 |
| Operating Cash Flow | -$10.61M | -$22.41M | $44,000.00 |
| Net Cash Flow from Continuing Financing Activities | $860,000.00 | $166.43M | $10.06M |
No comments yet — be the first to weigh in on KRSA.
Sign in to join the discussion.